MRK 560

a gamma-secretase inhibitor; MRK-560 is the (cis)-isomer; structure in first source

Also Known As:

MRK-560; MRK560; N-(4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)-1,1,1-trifluoromethanesulfonamide

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

1.	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/01/2019 - "Treatment of T-ALL cell lines with the selective PSEN1 inhibitor MRK-560 effectively decreased mutant NOTCH1 processing and led to cell cycle arrest. " 01/01/2019 - "These observations were extended to T-ALL patient-derived xenografts in vivo, demonstrating that MRK-560 treatment decreases leukemia burden and increased overall survival without any associated gut toxicity. " 01/01/2021 - "We also observed strong synergy between MRK-560 and KPT-8602 (eltanexor) in all NOTCH1-dependent T-ALL cell lines. " 01/01/2021 - "All NOTCH1-signaling-dependent T-ALL cell lines were sensitive to MRK-560 and its combination with ruxolitinib or imatinib in JAK1- or ABL1-dependent cell lines synergistically inhibited leukemia proliferation. " 01/01/2021 - "We treated T-ALL cell lines in vitro and T-ALL patient-derived xenograft (PDX) models in vivo with MRK-560 alone or in combination with other targeted inhibitors (ruxolitinib, imatinib or KPT-8602/eltanexor). "
2.	Leukemia 01/01/2019 - "These observations were extended to T-ALL patient-derived xenografts in vivo, demonstrating that MRK-560 treatment decreases leukemia burden and increased overall survival without any associated gut toxicity. " 01/01/2021 - "All NOTCH1-signaling-dependent T-ALL cell lines were sensitive to MRK-560 and its combination with ruxolitinib or imatinib in JAK1- or ABL1-dependent cell lines synergistically inhibited leukemia proliferation. "

1.	Amyloid Precursor Protein Secretases (beta-Secretase)
2.	Phosphotransferases (Kinase)
3.	Imatinib Mesylate (Gleevec)
4.	ruxolitinib
5.	Eltanexor